Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spinal Sarcopenia Cohort Study (SarcoSpine) (SarcoSpine)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03962530
Recruitment Status : Not yet recruiting
First Posted : May 24, 2019
Last Update Posted : June 12, 2019
Sponsor:
Collaborator:
National Research Foundation of Korea
Information provided by (Responsible Party):
Sang Yoon Lee, SMG-SNU Boramae Medical Center

Brief Summary:

Sarcopenia on lumbar paraspinal muscles is receiving renewed attention as a cause of spinal degeneration. However, there are few studies on the precise concept and diagnostic criteria for spinal sarcopenia. Here, we develop the concept of spinal sarcopenia in community-dwelling healthy elderly people. In addition, we aim to observe the natural aging course of paraspinal muscle and back muscle strength, and investigate the association between conventional sarcopenic indices and spinal sarcopenia.

This is a prospective observational cohort study with 120 healthy community-dwelling elderly people for 4 years. All subjects will be recruited according to no sarcopenia, possible sarcopenia, sarcopenia, and severe sarcopenia groups. The primary outcomes of this study are isokinetic back muscle strength and lumbar paraspinal muscle quantity and quality using lumbar spine MRI. Conventional sarcopenic indices and spine specific outcomes such as spinal sagittal balance, back performance scale, and Sorenson test will be also assessed. The data will be analysed using the intention-to-treat principle.


Condition or disease
Sarcopenia Spinal Disease

Detailed Description:

This is a prospective observational cohort study with 120 healthy community-dwelling elderly people in a single center (SMG-SNU Boramae Medical Center). Individual follow-up will last 4 years. Elderly people (≥ 65 years old) who are community-dwellers and able to walk with or without assistive devices) will be included. Sarcopenia can be divided by two stages: 1) possible sarcopenia (PS) defined by low handgrip strength and/or low gait speed and 2) sarcopenia (SA) confirmed by low handgrip strength and/or low gait speed and low muscle mass by the consensus report of the Asian working group for sarcopenia. No sarcopenia (NS) group is added to this classification, and the study participants are classified into three groups (NS, PS, and SA) after the screening tests. All outcome variables will be collected at baseline, 2 and 4 years. However, L-S spine MRI for lumbar paraspinal muscle quantity and quality will be performed only at baseline.

Data will be collected using a standardised data entry form and entered into the data management system. The intention-to-treat principle will be used for data analysis. Participant characteristics will be described using means and standard deviations for continuous data and frequencies and percentages for categorical data. The three groups will be compared using an analysis of variance (ANOVA) or the non-parametric equivalence Kruskal-Wallis test if required. To compare paired data (intra-group) between two different points, we will use repeated-measures ANOVA and Friedman tests for continuous and non-parametric data, respectively.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Sarcopenia of Spine: a Prospective Cohort Study
Estimated Study Start Date : August 2019
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2023



Primary Outcome Measures :
  1. Change of isokinetic back muscle strength [ Time Frame: Baseline, 24 months, and 48 months ]
    Isokinetic back extensor strength using Biodex

  2. Lumbar paraspinal muscle quantity and quality [ Time Frame: Baseline ]
    Lumbar paraspinal muscle examination using L-S spine MRI


Secondary Outcome Measures :
  1. Change of appendicular limb mass [ Time Frame: Baseline, 24 months, and 48 months ]
    Appendicular limb mass measure using wholebody DEXA and BIA

  2. Change of short physical performance battery [ Time Frame: Baseline, 24 months, and 48 months ]
    Physical performance measure by walking speed, balance test, and chair standing

  3. Laboratory test with biomarker [ Time Frame: Baseline, 24 months, and 48 months ]
    Serum IL-6 level

  4. Change of spinal sagittal balance [ Time Frame: Baseline, 24 months, and 48 months ]
    Spinopelvic parameters using simple whole spine X-ray

  5. Change of back performance scale [ Time Frame: Baseline, 24 months, and 48 months ]
    Sock Test, the Pick-up Test, the Roll-up Test, the Fingertip-to-Floor Test, and the Lift Test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Healthy elderly population who are community ambulator.
Criteria

Inclusion Criteria:

  1. Elderly people aged 65 and over;
  2. Community dweller;
  3. Ambulator with or without an assistive device.

Exclusion Criteria:

  1. low back pain with moderate severity (numeric rating scale 5 and over);
  2. history of any types of lumbar spine surgery;
  3. history of hip fracture surgery and arthroplasty of hip or knee;
  4. contraindications for MRI (such as cardiac pacemaker, implanted metallic objects, and claustrophobia);
  5. disorders in central nervous system (such as stroke, parkinsonism, spinal cord injury);
  6. cognitive dysfunction (Mini Mental State Examination score < 24);
  7. communication disorder (such as severe hearing loss);
  8. severe cardiopulmonary disease (such as heart failure with New York Heart Association Class III or IV);
  9. uncontrolled chronic disease (such as hypertension with systolic blood pressure >165 and diastolic blood pressure >95);
  10. musculoskeletal condition affecting physical function (such as amputation of limb);
  11. long term use of corticosteroids due to inflammatory disease;
  12. malignancy requiring treatment within 5 years; and
  13. other medical conditions which needs active treatment; patients who refuse to participate in a study will also be excluded.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sang Yoon Lee, Clinical associate professor, SMG-SNU Boramae Medical Center
ClinicalTrials.gov Identifier: NCT03962530    
Other Study ID Numbers: 20-2019-19
First Posted: May 24, 2019    Key Record Dates
Last Update Posted: June 12, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Diseases
Sarcopenia
Muscular Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Atrophy
Pathological Conditions, Anatomical
Bone Diseases
Musculoskeletal Diseases